

**UNITED STATES DEPARTMENT OF COMMERCE****Patent and Trademark Office**Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

MK

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/020, 743 02/09/98 MACK

D 018547-03480

020350 HM12/0413
TOWNSEND AND TOWNSEND AND CREW
TWO EMBARCADERO CENTER EIGHTH FLOOR
SAN FRANCISCO CA 94111

EXAMINER

STEW. T

ART UNIT PAPER NUMBER

9

1634
DATE MAILED:

04/13/99

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary	Application No. 09/020,743	Applicant(s) Mack
	Examiner Jeffrey Siew	Group Art Unit 1634

Responsive to communication(s) filed on _____.

This action is **FINAL**.

Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claims

Claim(s) 1-48 is/are pending in the application.

Of the above, claim(s) _____ is/are withdrawn from consideration.

Claim(s) _____ is/are allowed.

Claim(s) 1-48 is/are rejected.

Claim(s) _____ is/are objected to.

Claims _____ are subject to restriction or election requirement.

Application Papers

See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

The drawing(s) filed on _____ is/are objected to by the Examiner.

The proposed drawing correction, filed on _____ is approved disapproved.

The specification is objected to by the Examiner.

The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

All Some* None of the CERTIFIED copies of the priority documents have been

received.

received in Application No. (Series Code/Serial Number) _____.

received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

*Certified copies not received: _____.

Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

Notice of References Cited, PTO-892

Information Disclosure Statement(s), PTO-1449, Paper No(s). 5 (2 pgs)

Interview Summary, PTO-413

Notice of Draftsperson's Patent Drawing Review, PTO-948

Notice of Informal Patent Application, PTO-152

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES ---

Art Unit: 1634

DETAILED ACTION

The previous office action mailed 3/5 /99 is hereby withdrawn in light of this new office action.

Drawings

1. This application has been filed with informal drawings which are acceptable for examination purposes only. Formal drawings will be required when the application is allowed.

Specification

2. The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed.

The following title is suggested: Computer-aided display for Comparative Gene Expression

Claim Rejections - 35 USC § 112

3. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Art Unit: 1634

4. Claims 1-48 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

A) Claims 1-48 are confusing because it cannot be determined whether the two axis are connected.

B) Claims 1-48 are vague and indefinite because of the terms "position" and "relative" in claims 1,20,25,44,47 & 48. It cannot be determined what measure is used to define the meaning of "relative". It is suggested that position be amended to "position with X, Y coordinates where in the X position is selected relative to the first axis and Y axis etc". For subsequent claims 19 & 43 which involve a third axis, it is suggested to add Z coordinates. The use of these terms would have been well known and commonly practiced in the art of graphically displaying images.

C) Claims 1-48 are vague and indefinite because of the term "corresponding". Particularly in claims 1,20,25,44,47 & 48, it cannot be determined in what way or manner the "correspondence" is to occur.

Art Unit: 1634

D) Claim 4 recites the language "mark step" and depends on claim 1. However, proper antecedent basis is lacking in claim 1. Claim 4 depends on claim 1 which recites the language of

"displaying a mark". However, claim 1 does not recite a "mark step". It cannot be determined what the term is referring to.

E) Claim 6 recites the language " said monitoring step" and depends on claim 3. However, proper antecedent basis is lacking in claim 3. It cannot be determined to what monitoring step is being referred to.

F) Claim 25 recites the language "first and second". However, proper antecedent basis is lacking in claim 25 for these terms. It is suggested the claims be amended to include "a first and second".

G) Claim 6-10 are confusing because it cannot be determined to where the step of inputting is to occur. It cannot be determined whether the input is referring to the probe pair into the samples or the results into a computer for display.

Art Unit: 1634

- H) Claim 6 is confusing because it cannot be determined at what point the steps are to be performed in relationship to the steps in claims 1 & 6. It is suggested that a phrase be included in the preamble reciting “wherein the comparing step” further comprises”.
- I) Claim 10 & 34 are confusing because of the term “pairs that cause” because it cannot be determined as to what the pairs are to cause.
- J) Claim 9 is rejected under 35 U.S.C. 112, second paragraph, as being incomplete for omitting essential steps, such omission amounting to a gap between the steps. See MPEP § 2172.01. The omitted steps are: computing the IDIF between the Ipm-Imm. Clarification is requested.
- K) Claim 10 & 34 are rejected under 35 U.S.C. 112, second paragraph, as being incomplete for omitting essential steps, such omission amounting to a gap between the steps. See MPEP § 2172.01. The omitted steps are: averaging the IDEF values. The specification discloses that the determination of expression is based on several calculations may be used to calculate the expression level (see page 11, lines 5-14). However in using the calculation of the sum of IDEF values as recited in claim 10 would necessitate an averaging step.

Art Unit: 1634

L) Claim 11& 35 are confusing because of the phrase “user input selecting said mark” is not grammatically correct. It cannot be determined what the phrase is referring to. It is suggested the phrase be amended to “ an input of a user’s selection of said mark”.

M) Claims 11,12 & 36 are confusing because of the term “information”. It cannot be determined to what or what type of information is to be displayed. The rejection would be overcome if the claims were to be amended to include “comprises a GENBANK accession number”.

N) Claim 17& 41 are confusing because it cannot be determined “ treatment strategy”. It cannot be determined how a characteristic comprises a “ treatment strategy”.

O) Claims 16 & 40 are confusing because of the phrase “presence of disease”. Although disease level or state are commonly used, the use of “presence” would more likely refer to an actual physical presence such as a bacteria or virus. It is suggested that the claim be amended to “disease state”.

P) Claim 30 recites the language “ said monitoring step” and depends on claim 3. However, proper antecedent basis is lacking in claim 27. It cannot be determined to what monitoring step is being referred to.

Art Unit: 1634

Claim Rejections - 35 USC § 102

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

6. Claims 1-5, 20,21 & 23 are rejected under 35 U.S.C. 102(b) as being anticipated Zhao et al (Gene Vol. 156 pp. 207-213 1995).

Claims 1-5, 20,21 & 23 are drawn to displaying expression levels or compound concentration of two samples on a graph in which the first axis corresponds to expression level of first sample and the second axis is perpendicular to first axis and corresponds to expression level of second sample and a mark is displayed.

Zhao et al teach bioimaging analyzer system to compare the expression profiles of thousands of genes cDNAs) simultaneously . They teach the a high density cDNA filter analysis in which expression profiles of 2505 cloned human brain cDNAs (genes) were monitored (see whole document esp. Abstract). A quantitative analysis of the filter is performed using Fuji Bioimaging Analyzer BAS2000 System and automated quantification program AutoQuant. The final part is sequence analysis in which each clone is characterized by homology search in the GENBANK nucleotide Sequence Database (see page 208 & Figure 1). They applied the system for the

Art Unit: 1634

comparative analysis of expression profile of the human cDNAs in brain. The expression profiles were illustrated on graphs by comparing their scores from two tissues with Microsoft Excel (Microsoft) on a Macintosh personal computer(see page 210-211 and fig. 3). A mark for each gene is positioned relative to the expression levels in the two different samples.

Claim Rejections - 35 USC § 103

7. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) a patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

8. Claims 25-29,44,45,47 & 48 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Zhao et al (Gene Vol. 156 pp. 207-213 1995).

Claims 25-29,44 & 45 are drawn to a software product that contains code that displays on first axis expression level or compound in first sample, displays on second axis an expression level or compound in second sample, displays a mark whose position is relative to first or second axis.

Art Unit: 1634

Claim 47 is drawn to computer system comprising display, processor and memory for displaying a first axis corresponding to expression level of first axis, code for displaying a first axis corresponding to expression level of first axis and code for displaying a mark , a computer readable storage medium for storing codes.

Claims 48 is drawn to computer system comprising display, processor and memory for displaying a first axis corresponding to a compound concentration, code for displaying a first axis corresponding to compound concentration and code for displaying a mark , a computer readable storage medium for storing codes.

Zhao et al teach bioimaging analyzer system to compare the expression profiles of thousands of genes cDNAs simultaneously . They teach a high density cDNA filter analysis in which expression profiles of 2505 cloned human brain cDNAs (genes) were monitored (see whole document esp. Abstract). A quantitative analysis of the filter is performed using Fuji Bioimaging Analyzer BAS2000 System and automated quantification program AutoQuant. The final part is sequence analysis in which each clone is characterized by homology search in the GENBANK nucleotide Sequence Database (see page 208 & Figure 1). They applied the system for the comparative analysis of expression profile of the human cDNAs in brain. The expression profiles were illustrated on graphs by comparing the their scores from two tissues with Microsoft Excel (Microsoft) on a Macintosh personal computer(see page 210-211 and fig. 3). A mark for each gene is positioned relative to the expression levels in the two different samples. Although the reference is silent to the teaching of “code”, it was well known and commonly practiced that

Art Unit: 1634

Microsoft Excel (see page 211) is a software product containing code used to generate graphs. Through the use of this code, Zhao et al generated the graphs depicted in Figure 3 to compare the expression level of two different samples. Moreover, the computer used was a Macintosh computer(see page 211) as depicted in Figure 1. Although the reference is silent to the teaching of processor, memory and display, the personal computer inherently contains a display, microprocessor and memory in the form of RAM, ROM and hard disk.

In the alternative one of ordinary skill in the art would have been motivated to implement the Microsoft Excel program in code format to display the expression level in order to analyze various data inputs from various samples on different platforms. A program code provides versatility in allowing dynamic input to be analyzed. It would have been advantageous to implement analysis and display on code so that a large number of different samples would be analyzed especially over time. Moreover, the implementation on code would allow the analysis to be performed across different platforms and even different machines. It would have been prima facie obvious to implement the display of the expression levels through a computer code comprising code in order to analyze and display a constantly changing and new input across different platforms and machines.

Moreover, in the alternative one of ordinary skill in the art would have been motivated to display the expression level on a computer system containing display, processor and memory in order to analyze various data inputs from various samples. A computer system provides excellent data storage and data manipulation capabilities. It would have been advantageous to implement

Art Unit: 1634

analysis and display on a computer system so that a large number of different samples would be analyzed. It would have been prima facie obvious to implement the display of the expression levels on a computer system in order to analyze large amounts of data efficiently.

9. Claim 19 & 43 are rejected under 35 U.S.C. 103(a) as being unpatentable over Zhao et al (Gene Vol. 156 pp. 207-213 1995).

Claim 19 is drawn to claim 1 with the further limitation of displaying third axis wherein the mark is position relative to expression level of a third sample.

Claim 43 is drawn to claim 25 a computer product with the further limitation of having code displaying third axis wherein the mark is position relative to expression level of a third sample

The teachings or suggestions of Zhao et al are described previously, briefly they teach bioimaging analyzer system to compare the expression profiles of thousands of genes cDNAs simultaneously. They teach the a high density cDNA filter analysis in which expression profiles of 2505 cloned human brain cDNAs (genes) were monitored (see whole document esp. Abstract). A quantitative analysis of the filter is performed using Fuji Bioimaging Analyzer BAS2000 System and automated quantification program AutoQuant. The final part is sequence analysis in which each clone is characterized by homology search in the GENBANK nucleotide Sequence Database (see page 208 & Figure 1). They applied the system for the comparative analysis of expression profile of the human cDNAs in brain. The expression profiles were illustrated on graphs by

Art Unit: 1634

comparing the their scores from two tissues with Microsoft Excel (Microsoft) on a Macintosh personal computer(see page 210-211 and fig. 3). A mark for each gene is positioned relative to the expression levels in the two different samples. Although the reference is silent to the teaching of "code", it was well known and commonly practiced that Microsoft Excel (see page 211) is a software product containing code used to generate graphs. Through the use of this code, Zhao et al generated the graphs depicted in Figure 3 to compare the expression level of two different samples. Moreover, the computer used was a Macintosh computer(see page 211) as depicted in Figure 1. Although the reference is silent to the teaching of processor, memory and display, it was well known and commonly practiced in the art that personal computer contains a display, microprocessor and memory in the form of RAM, ROM and hard disk.

Zhao et al do not teach a third axis.

One of ordinary skill in the art would have been motivated to apply a third axis to Zhao et al display format in order to further compare the expression level in a third sample. It would have been advantageous to use a 3D format to compare three samples at the same time so that comparisons would be visually easier to interpret and would be performed simultaneously. It would have been prima facie obvious to apply a third axis to Zhao et al's display format in order to analyze more information at the same time.

Art Unit: 1634

10. Claims 6-18 & 30-42 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lockhart et al (WO97/27317 21 July 1997) in view of Zhao et al (Gene Vol. 156 pp. 207-213 1995).

Claims 6-18 are drawn to claim 1 in which the expression level of expressed sequence is monitored.

Claims 30-42 are drawn to computer product comprising code for displaying a first axis corresponding to expression level of first axis, code for displaying a first axis corresponding to expression level of first axis and code for displaying a mark , a computer readable storage medium for storing codes.

Lockhart et al teach a method of detecting nucleic abundances or concentrations (e.g. expression levels) between two or more samples (see whole document esp. abstract). They teach the simultaneous monitoring of the expression of a multiplicity of genes using perfect match probe and mismatch probes (see page 5,12,47 & esp. 49-50). They teach that expression monitoring would be useful for both drug safety and toxicology screenings (see page 230) and monitoring various genes in response to defined stimuli such as drugs (see page 22). They teach that monitoring of gene expression may be performed using a computer system running a software program that includes computer code incorporating analysis of hybridization intensities of the screens(see page 90 & Figure 6-8). They teach a method of comparing expression level using the hybridization intensities between the perfect match and mismatch probes (see page 93-101 & Figure 9-10B). They compare the hybridization intensity difference and ratio of the perfect match

Art Unit: 1634

and mismatch probes with a threshold. The values NPOS, NNEG and LR are calculated for each pair of probes. The analysis is repeated to calculate the average of the differences. They teach that oligonucleotide pairs that show the greatest differential hybridization between two samples can be identified by sorting the observed hybridization ratio and difference values. Based on identified oligonucleotide pair sequences, a gene can be searched for in sequence databases such as GENBANK (see page 128-9). They also display the results in a graph showing differential expression between samples (see Figures 16-17).

Lockhart et al do not teach presenting expression level information by displaying on a first axis representing the expression level in a first sample, displaying on second axis representing the expression level in the second axis and displaying a mark relative to the two axes.

Zhao et al teach bioimaging analyzer system to compare the expression profiles of thousands of genes cDNAs) simultaneously . They teach the a high density cDNA filter analysis in which expression profiles of 2505 cloned human brain cDNAs (genes) were monitored (see whole document esp. Abstract). A quantitative analysis of the filter is performed using Fuji Bioimaging Analyzer BAS2000 System and automated quantification program AutoQuant. The final part is sequence analysis in which each clone is characterized by homology search in the GENBANK nucleotide Sequence Database (see page 208 & Figure 1). They applied the system for the comparative analysis of expression profile of the human cDNAs in brain. The expression profiles were illustrated on graphs by comparing the their scores from two tissues with Microsoft Excel (Microsoft) on a Macintosh personal computer(see page 210-211 and fig. 3).

Art Unit: 1634

One of ordinary skill in the art would have been motivated to display the comparative expression levels of genes as in Zhao et al's to Lockhart et al's analysis technique in order to compare the gene expression between two different samples. Zhao et al's display format allows easy visualization of the many different expressions of genes between two samples. It would have been prima facie obvious to construct a graph with an axis representing the gene expression in one sample and another axis representing the gene expression in a second sample in order to compare the differential gene expression between the different samples.

9. Claims 22, 24 & 46 are rejected under 35 U.S.C. 103(a) as being unpatentable over Zhao et al in view of Beattie (US5,843,767 December 1, 1998).

Claims 22 & 24 are drawn to claim 20 with the added limitation the polymer is a protein.

Claim 46 is drawn to claim 44, a computer product with the added limitation the polymer is a protein.

The teachings and suggestions of Zhao et al are described above.

Zhao et al do not teach the use of protein polymers.

Beattie et al teach the use of protein probes such as antibodies in hybridization array (see whole document).

One of ordinary skill in the art would have been motivated to apply Beattie et al's teaching of using protein probes to Zhao et al's expression display in order to compare the expression level of actual translated protein between two samples. Beattie states that the use of antibodies or

Art Unit: 1634

ligand receptor binding would be applicable to the study of identifying biomolecules. It was well known and commonly practiced to use these ligand -receptor binding techniques in order to actually identify the stage of gene expression i.e. the translated protein. It would have been prima facie obvious to use Beattie's protein probes and display the results between two samples using Zhao et al's expression method in order to compare the protein levels which represent the final stage of gene expression.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey Siew whose telephone number is (703) 305-3886 and whose e-mail address is jsiew@uspto.gov. The examiner can normally be reached on Monday through Friday from 6:30 a.m. to 3 p.m. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones, can be reached on (703) 308-1152.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist for Technology Center 1600 whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Center numbers for Group 1600 are Voice (703) 308-3290 and Fax (703) 305-3014 or (703) 305-4242.

Art Unit: 1634

J. Siew

Jeffrey Siew

March 29, 1999

KENNETH R. HORLICK
PRIMARY EXAMINER
GROUP 1800 1600 3/29/99

Kenneth R. Horlick, Ph.D.